A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do
not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study,
investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and
atezolizumab will result in better therapeutic value.